$1.53 (1.32%)

Volume: 41.498k

Closed: Mar 21, 2023

Hollow Logo Score: -1.027
Cellectar Biosciences Stock
$1.53 (1.32%)

Volume: 41.498k

Closed: Mar 21, 2023

Score Hollow Logo -1.027

Cellectar Biosciences Stock Company Profile

100 Campus Drive

Florham Park NJ 07932

608 441 8120


Industry: Biotechnology

Sector: Healthcare

Cellectar Biosciences


Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE